SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab (RKLB) is trending following its substantial $805 million contract award from the Space Development Agency, solidifying its position among major defense primes. The community is buzzing with excitement over this significant validation and the company's accelerated U.S. Space Force mission, viewing RKLB as a pivotal long-term player in the rapidly expanding space sector with high anticipation for its upcoming Neutron rocket developments.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing significant volatility following its announced merger with a nuclear fusion company, TAE Technologies, prompting intense community discussion. Many perceive this strategic pivot as a groundbreaking move into future energy and AI infrastructure, fueling speculation of a massive short squeeze and long-term potential. Conversely, a vocal contingent views the development with skepticism, labeling it a "scam" or "pump and dump" given the company's prior trajectory and the nascent stage of fusion technology.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as excitement builds around its expanded hands-free driving features and robust AI strategy, including custom chips and the anticipated R2 platform. The community is actively discussing recent analyst re-ratings that highlight its long-term potential, fueling a strong "short squeeze" narrative as the stock approaches new highs. This momentum reflects a growing conviction in Rivian's technological advancements and future competitive position in the EV market.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending upward, primarily fueled by its pivotal announcement of joining the U.S. Department of Energy's Genesis Mission, which is viewed by the community as a significant validation and a de-risking catalyst. This news, alongside broader positive sentiment for AI infrastructure, has reportedly ignited a short squeeze, rewarding patient investors while prompting intense debate among market participants.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending with significant bullish momentum, largely fueled by a recent KeyBanc "Overweight" rating and a $20 price target, alongside widespread anticipation for the imminent NASA Lunar Terrain Vehicle (LTV) contract award. The community is actively discussing the stock's high short interest, speculating on a potential squeeze, and highlighting the broader sector enthusiasm for lunar exploration and infrastructure as key drivers for substantial upside.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending due to significant developments, including the completion of its Roboteam acquisition, strategic partnership discussions with HEIDELBERG for European expansion, and successful AI-powered demining pilot programs. Analysts have initiated and raised coverage, fueling community speculation about a potential short squeeze and massive long-term growth driven by increased global defense spending on autonomous and counter-drone systems. Despite market volatility, many investors express strong conviction in the company's future, anticipating major contract announcements.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following a significant stock decline, despite exceeding revenue and earnings estimates, as investors reacted negatively to reports of declining sales in Greater China and pressured profit margins. The community is sharply divided, with many viewing the dip as an overreaction and a long-term buying opportunity, while others remain concerned about ongoing challenges in China and rising competition.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival (CCL) is trending after recent strong financial results and the significant reinstatement of its quarterly dividend, signaling a notable turnaround for the company. The community is actively discussing its improved profitability and record booking volumes, fueling bullish sentiment for both Carnival and the broader cruise sector. This positive momentum offers reassurance amid prior market concerns, with many anticipating further upside.

Lamb Weston Holdings, Inc. engages in the production, distribution, and marketing of value-added frozen potato products. It operates through the North America and International segments. The North America segment includes frozen potato products sold in the United States, Canada, and Mexico to quick service and full-service restaurants and chains, foodservice distributors, non-commercial channels, and retailers. International segment primarily includes frozen potato products sold outside of North America. The company was founded in 1950 and is headquartered in Eagle, ID.

Lamb Weston Holdings Inc

Lamb Weston is trending after reporting weaker-than-expected earnings and a lowered outlook, compounded by a leadership transition and restructuring initiatives. Despite a sharp decline in shares, many in the community are actively debating whether the sell-off is overdone, with some "buying the dip" on the belief in resilient demand for frozen potato products. The conversation is further fueled by activist investor engagement hinting at potential strategic changes for the company.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending after securing a development loan facility to fund new AI data center projects, seen by many as strong institutional validation of its growth strategy. This non-dilutive financing, coupled with ongoing advanced negotiations for multiple campuses with an investment-grade hyperscaler, is fueling community discussions about a potential short squeeze and a very bullish outlook for the company in the rapidly expanding AI infrastructure sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month Low - Here's What Happened

Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low - Should You Sell...

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received a consensus rating of "Moderate Buy" from the sixteen brokerages that are presently covering the company, MarketBeat...

Janux Therapeutics (NASDAQ:JANX) Reaches New 52-Week Low - What's Next?

Janux Therapeutics (NASDAQ:JANX) Hits New 1-Year Low - Should You Sell...

Stempoint Capital LP Has $2.08 Million Stock Position in Janux Therapeutics, Inc. $JANX

Stempoint Capital LP lessened its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 73.7% in the second quarter, according to the company in its most recent disclosure with the...

Janux Therapeutics (NASDAQ:JANX) Sees Large Volume Increase - Time to Buy?

Janux Therapeutics (NASDAQ:JANX) Sees Large Volume Increase - Here's What Happened...

Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 3,333 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,333 shares of the company's stock in a transaction dated Monday, December 1st. The stock was sold at an...

Janux Therapeutics Enters Oversold Territory (JANX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

<ul class="summary-bullets"><li>Analysts flagged missing timelines and lingering questions in the JANX007 Phase 1 update.</li><li>Several firms also kept bullish ratings, calling the sell-off disproportionate.</li><li>Retail traders on Stocktwits pointed to low float dynamics and average targets far above current levels.</li></ul>Shares of Janux Therapeutics (JANX) fell nearly 50% on Tuesday after several analysts lowered their price targets following the company’s updated Phase 1 interim results for JANX007, its experimental prostate cancer drug currently being tested in patients with metastatic castration-resistant prostate cancer (mCRPC).&nbsp;Janux reported durable responses, a radiographic progression-free survival (rPFS) of 7.9–8.9 months, deep declines in prostate-specific antigen (PSA), and a manageable safety profile for cytokine release syndrome (CRS), a common immune-related side effect. Early-stage results in patients who had not previously received taxane chemotherapy were also described as “encouraging.”While the company called the update positive, analysts said the dataset raised concerns that contributed to the stock’s steep fall.<h2 class="st-heading-2">Missing Timelines And Unanswered Questions&nbsp;</h2>Cantor Fitzgerald analyst Josh Schimmer cut his price target to $150 from $200 while keeping an ‘Overweight’ rating. Schimmer said the new data answered some important questions but still left “a handful of remaining variables and blanks to fill in.” He noted that Janux did not provide timelines for when investors can expect the next clinical update or regulatory milestone.&nbsp;<h2 class="st-heading-2">Mixed Efficacy Signals&nbsp;</h2>H.C. Wainwright reduced its price target to $45 from $70 and maintained a ‘Buy’ rating. The firm said the drug’s overall effectiveness weakened on certain key measures, describing the data as “mixed.” It added that JANX007 will likely be a “show me” story, meaning investors will wait for more mature, clearer results before regaining confidence.Bank of America Securities (BofA) also called the update “admittedly mixed,” while cutting its target to $49 from $58 and keeping a ‘Buy’ rating.The firm said JANX007 is still “a viable drug with a reasonable safety profile” and may eventually show an improvement in overall survival (OS) compared with Novartis’s Pluvicto, another prostate cancer therapy. However, BofA has now pushed its expected launch to 2028 and lowered its predicted peak market share to 15% from 20%.Stifel analyst Stephen Willey echoed the mixed tone, saying there were “some positives to extract” but also ongoing questions about the dataset. He lowered his price target to $38 from $46 while keeping a ‘Buy’ rating and said the near-term catalyst calendar doesn’t set up great. Even so, Willey said he “struggles to rationalize” the drop in the stock.<h2 class="st-heading-2">Stock Slide Viewed As Excessive&nbsp;</h2>Bank of America said the stock’s decline appears “overdone,” even after adopting more cautious assumptions. Cantor Fitzgerald also said the selloff looks overdone and called the current valuation “a compelling entry point.”Clear Street lowered its price target to $32 from $80 while maintaining a ‘Buy’ rating. The firm said its cut reflects a "more pragmatic" market entry timeline and said the updated data show a “thoughtful development process.”&nbsp;<h2 class="st-heading-2">Stocktwits Traders Brace For A Sharp Rebound Rally</h2>On Stocktwits, retail sentiment for Janux was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:972/142;" src="https://news.stocktwits-cdn.com/janx_ss_png_89a213ee1a.webp" alt="janx ss.png" width="972" height="142"><figcaption>JANX sentiment and message volume as of December 2| Source: Stocktwits</figcaption></figure>One user said, “the FOMO is going to hit hard with the sideliners watching when the rebound rally kicks off.”<stembedurl>https://stocktwits.com/RainMan_17/message/637910370</stembedurl>Another bullish trader suggested the stock sits in a retail-driven sweet spot, highlighting the low float, small-cap setup, the “massive discount,” and average targets in the $70–$77 range. They also argued the drop was a “clear overreaction.”<stembedurl>https://stocktwits.com/RainMan_17/message/637909276</stembedurl><a href="https://stocktwits.com/symbol/JANX">Janux’s stock</a> has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Janux’s stock (JANX) has declined 67% so far in 2025. (Photo credit: Getty Images)

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound 

Janux shares plunged after the JANX007 trial update prompted widespread target cuts, even as retail traders framed the selloff as poised for a rebound.

Equity

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Current Price	$14.19
Prev Close	$14.04
Open	$14.10
Dividend Yield	0.00%
50-Day Moving Average	$25.05
Beta	1.46
Avg. Volume	1.09M
PE Ratio	-8.38

52-Week High	$61.59
52-Week Low	$13.80
Market Capitalization	$850.65M
EPS (Annual)	-$1.28
Price to Book	0.86
Revenue Per Employee	$130,716.05
Enterprise Value/EBITDA	N/A

JANX
Janux Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JANX News

JANXJanux Therapeutics Inc